Publicação: Boron in drug design: Recent advances in the development of new therapeutic agents
Carregando...
Data
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Elsevier B.V.
Tipo
Resenha
Direito de acesso
Resumo
Advances in the field of boron chemistry have expanded the application of this element in Medicinal Chemistry. Boron-containing compounds represent a new class for medicinal chemists to use in their drug designs. Bortezomib (Velcade (R)), a dipeptide boronic acid approved by the FDA in 2003 for treatment of multiple myeloma, paved the way for the discovery of new boron-containing compounds. After its approval, two other boron-containing compounds have been approved, tavaborole (Kerydin (R)) for the treatment of onychomicosis and crisaborole (Eucrisa (R)) for the treatment of mild to moderate atopic dermatitis. A number of boron-containing compounds have been described and evaluated for a plethora of therapeutic applications. The present review is intended to highlight the recent advances related to boron-containing compounds and their therapeutic applications. Here, we focused only in those most biologically active compounds with proven in vitro and/or in vivo efficacy in the therapeutic area published in the last years. (C) 2019 Elsevier Masson SAS. All rights reserved.
Descrição
Palavras-chave
Boron, Drug design, Boron-containing compounds, Biological activity, Boronic acids, Benzoxaboroles
Idioma
Inglês
Como citar
European Journal Of Medicinal Chemistry. Issy-les-moulineaux: Elsevier France-editions Scientifiques Medicales Elsevier, v. 179, p. 791-804, 2019.
